- Home
- KPRX vs SYTA Comparison
KPRX vs SYTA Comparison
Compare KPRX & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- SYTA
- Stock Information
- Founded
- KPRX 1998
- SYTA N/A
- Country
- KPRX United States
- SYTA Canada
- Employees
- KPRX N/A
- SYTA 24
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SYTA Telecommunications Equipment
- Sector
- KPRX Health Care
- SYTA Telecommunications
- Exchange
- KPRX Nasdaq
- SYTA Nasdaq
- Market Cap
- KPRX 9.1M
- SYTA 10.7M
- IPO Year
- KPRX N/A
- SYTA 2020
- Fundamental
- Price
- KPRX $2.90
- SYTA $2.03
- Analyst Decision
- KPRX Strong Buy
- SYTA
- Analyst Count
- KPRX 1
- SYTA 0
- Target Price
- KPRX $10.00
- SYTA N/A
- AVG Volume (30 Days)
- KPRX 1.3M
- SYTA 2.0M
- Earning Date
- KPRX 08-08-2025
- SYTA 08-15-2025
- Dividend Yield
- KPRX N/A
- SYTA N/A
- EPS Growth
- KPRX N/A
- SYTA N/A
- EPS
- KPRX N/A
- SYTA N/A
- Revenue
- KPRX $20,000.00
- SYTA $11,740,024.00
- Revenue This Year
- KPRX N/A
- SYTA $18.41
- Revenue Next Year
- KPRX N/A
- SYTA N/A
- P/E Ratio
- KPRX N/A
- SYTA N/A
- Revenue Growth
- KPRX N/A
- SYTA 33.58
- 52 Week Low
- KPRX $2.51
- SYTA $0.93
- 52 Week High
- KPRX $4.86
- SYTA $162.90
- Technical
- Relative Strength Index (RSI)
- KPRX 43.33
- SYTA 43.33
- Support Level
- KPRX $2.87
- SYTA $1.83
- Resistance Level
- KPRX $3.22
- SYTA $2.30
- Average True Range (ATR)
- KPRX 0.18
- SYTA 0.32
- MACD
- KPRX -0.02
- SYTA -0.13
- Stochastic Oscillator
- KPRX 5.77
- SYTA 12.12
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.